Children's Oncology Group's 2023 blueprint for research: Rare tumors.
Kris Ann P SchultzMurali ChintagumpalaJin PiaoKenneth S ChenRobyn D GartrellEmily Christison-LagayJesse L BerryRachana ShahTheodore W Laetschnull nullPublished in: Pediatric blood & cancer (2023)
The Children's Oncology Group (COG) Rare Tumor Committee includes the Infrequent Tumor and Retinoblastoma subcommittees, encompassing a wide range of extracranial solid tumors that do not fall within another COG disease committee. Current therapeutic trial development focuses on nasopharyngeal carcinoma, adrenocortical carcinoma, pleuropulmonary blastoma, colorectal carcinoma, melanoma, and thyroid carcinoma. Given the rarity of these tumors, novel strategies and international collaborative efforts are necessary to advance research and improve outcomes.